Erratum to “Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study”

Documenti analoghi

• Review of patient‐reported outcomes in EMPOWER‐Lung 1 in patients with advanced non‐small cell lung cancer treated with cemiplimab versus chemotherapy
  di: David R. Gandara, et al.
  Pubblicazione: (2026)
• Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%
  di: Saadettin Kilickap, et al.
  Pubblicazione: (2025)
• A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
  di: Tao Li, et al.
  Pubblicazione: (2024)
• Efficacy of first‐line treatment options beyond RET‐TKIs in advanced RET‐rearranged non‐small cell lung cancer: A multi‐center real‐world study
  di: Yihui Ge, et al.
  Pubblicazione: (2024)
• Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer
  di: Shuta Ohara, et al.
  Pubblicazione: (2024)